Histologic features are important prognostic indicators in early stages lung adenocarcinomas

Modern Pathology

Volumn 20, Issue 2, 2007, Pages 233-241

  Yim, Joon ^a   Zhu, Lee Ching ^a   Chiriboga, Luis ^a   Watson, Heather N ^a   Goldberg, Judith D ^a   Moreira, Andre L ^a,b  

^a NEW YORK UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

Author keywords

Bronchioloalveolar carcinoma; Histological classification; Lung adenocarcinoma; Prognosis

Indexed keywords

KI 67 ANTIGEN; PROTEIN P53;

ADULT; AGE DISTRIBUTION; AGED; ARTICLE; CANCER CLASSIFICATION; CANCER GROWTH; CANCER PATIENT; CANCER SIZE; CANCER SURVIVAL; CHEMICAL LABELING; CONTROLLED STUDY; DATA BASE; FEMALE; HISTOLOGY; HUMAN; HUMAN TISSUE; INVASIVE CARCINOMA; LUNG ADENOCARCINOMA; LUNG CARCINOMA; LYMPH NODE METASTASIS; MALE; MEDICAL RECORD REVIEW; PRIORITY JOURNAL; PROGNOSIS; PROTEIN EXPRESSION; STATISTICAL ANALYSIS; STATISTICAL SIGNIFICANCE;

ADENOCARCINOMA; AGED; CELL COUNT; CELL PROLIFERATION; HUMANS; IMMUNOENZYME TECHNIQUES; KI-67 ANTIGEN; LUNG NEOPLASMS; LYMPH NODES; MIDDLE AGED; NEOPLASM STAGING; PROGNOSIS; SURVIVAL RATE; TUMOR MARKERS, BIOLOGICAL; TUMOR SUPPRESSOR PROTEIN P53;

EID: 33947262610     PISSN: 08933952     EISSN: 15300285     Source Type: Journal    
DOI: 10.1038/modpathol.3800734     Document Type: Article

References (30)

1. Travis WD, Brambilla E, Muller-Hermelink HK, et al. Pathology and Genetics: Tumours of the Lung, Pleura, Thymus and Heart. World Health Organization Classification of Tumours. IARC press: Lyon, 2004.
2. Noguchi M, Morikawa A, Kawasaki M, et al. Small adenocarcinomas of the lung. Histologic characteristics and prognosis. Cancer 1995;15:2844-2852.
3. Yokose T, Suzuki K, Nagai K, et al. Favorable and unfavorable morphological prognosis factors in peripheral adenocarcinoma of the lung 3 cm or less in diameter. Lung Cancer 2000;29:179-188.
4. Susuki K, Yokose T, Yoshida J, et al. Prognostic significance of the size of central fibrosis in peripheral adenocarcinoma of the lung. Ann Thorac Surg 2000;69:893-897.
5. Ebright MI, Zakowski MF, Martin J, et al. Clinical pattern and pathological stage but not histologic features predict outcome for bronchioloalveolar carcinoma. Ann Thorac Surg 2002;74:1640-1647.
6. Sakurai H, Dobashi Y, Mizutani E, et al. Bronchioloalveolar carcinoma of the lung 3 centimeters or less in diameter: a prognostic assessment. Ann Thorac Surg 2004;78:1728-1733.
7. Sakurai H, Maeshima A, Watanabe S, et al. Grade of stromal invasion in small adenocarcinoma of the lung. Histological minimal invasion and prognosis. Am J Surg Pathol 2004;28:198-206.
8. Fleming ID, Cooper JS, Henson DE, et al. AJCC Cancer Staging Manual, 5th edn. American Cancer Society, Lippincot Williams & Wilkins: Philadelphia, PA.
9. Ishida H, Irie K, Itoh T, et al. The prognostic significance of p53 and bcl-2 expression in lung adenocarcinoma and its correlation with Ki-67 growth fraction. Cancer 1997;80:1034-1045.
10. Quinlan DC, Davidson AG, Summers CL, et al. Accumulation of P53 protein correlates with poor prognosis in human lung cancer. Cancer Res 1992;52:4828-4831.
11. Fujino M, Dosaka-Akita H, Harada M, et al. Prognostic significance of p53 and ras p21 expression in nonsmall cell lung cancer. Cancer 1995;76:2457-2463.
12. Terasaki H, Niki T, Matsuno Y, et al. Lung adenocarcinoma with mixed bronchioloalveolar and invasive components. Clinicopathological features, subclassification by extent of invasive foci, and immunohistochemical characterization. Am J Surg Pathol 2003;27:937-951.
13. Roh MS, Lee JI, Choi PJ, et al. Relationship between micropapillary components in the regional lymph nodes of patients with stage I lung adenocarcinomas. Histopathology 2004;45:580-586.
14. Makimoto Y, Nabeshima K, Iwasaki H, et al. Micropapillary pattern: a distinctive pathological marker to subclassify tumors with a significantly poor prognosis within small peripheral lung adenocarcinoma (
15. Travis WD, Garg K, Franklin WA, et al. Evolving concepts in the pathology and computed tomography imaging of lung adenocarcinoma and bronchioloalveolar carcinoma. J Clin Oncol 2005;23:3279-3287.
16. Zell JA, Ignatious Ou SH, Ziogas A, et al. Epidemiology of bronchioloalveolar carcinoma: improvement in survival after release of the 1999 WHO Classification of lung tumors. J Clin Oncol 2005;23:8396-8405.
17. Rena O, Papalia E, Ruffini E, et al. Stage I pure bronchioloalveolar carcinoma: recurrences, survival and comparison with adenocarcinoma of the lung. Eur J Cardiothoracic Surg 2003;23:409-414.
18. Okubo K, Mark EJ, Flieder D, et al. Bronchioloalveolar carcinoma: clinical, radiologic, and pathologic factors and survival. J Thorac Cardiovasc Surg 1999;118:702-709.
19. Gerdes J, Lemke H, Baisch H, et al. Cell cycle analysis of a cell proliferation-associated human nuclear antigen defined by the monoclonal antibody Ki-67. J Immunol 1984;133:1710-1715.
20. Schwarting R. Little missed markers and Ki-67. Lab Invest 1993;68:597-599.
21. Pence JC, Kerns BJ, Dodge RK, et al. Prognostic significance of the proliferation index in surgically resected non-small cell lung cancer. Arch Surg 1993;128:1382-1390.
22. Scagliotti GV, Micela M, Gubetta L, et al. Prognostic significance of Ki-67 labeling in resected non-small cell lung cancer. Eur J Cancer 1993;3:363-365.
23. Harris CC, Hollstein M. Clinical implications of the p53 tumor-suppressor gene. N Engl J Med 1993;329:1318-1327.
24. Kawasaki M, Noguchi M, Morikawa A, et al. Nuclear p53 accumulation by small-sized adenocarcinomas of the lung. Pathol Int 1996;46:486-490.
25. Li ZH, Zheng J, Weiss LM, et al. C-k-ras and p53 mutations occur very early in adenocarcinoma of the lung. Am J Pathol 1994;144:303-309.
26. Westra WH, Offerhaus GJ, Goodman SN, et al. Overexpression of p53 tumor suppressor gene product in primary lung adenocarcinomas is associated with cigarette smoking. Am J Surg Pathol 1993;17:213-220.
27. Hoffmann H. Resected non-small cell lung cancer stage I/II: indication for adjuvant/neoadjuvant therapy? Lung Cancer 2004;45(suppl 2):S91-S97.
28. Pisters KMW, Le Chevalier T. Adjuvant chemotherapy in completely resected non-small cell lung cancer. J Clin Oncol 2005;23:3270-3278.
29. Sakao Y, Sakuragi T, Natsuaki M, et al. Clinicopathological analysis of prognostic factors in clinical IA peripheral adenocarcinoma of the lung. Ann Thorac Surg 2003;75:1113-1117.
30. Susuki K, Nagai K, Yoshida J, et al. Prognostic factors in clinical stage I non-small cell lung cancer. Ann Thorac Surg 1999;67:927-932.